EGFR and cancer: Previous studies have shown that combining aspirin with erlotinib enhanced the effects of erlotinib in killing EGFR‐mutant NSCLC cells (Hu et al., 2018; Song et al., 2018) and that combining aspirin with sorafenib and other drugs significantly suppressed cancer growth and prolonged remission in xenograft models (Amaral et al., 2018; Miao et al., 2018; Xia et al., 2017; Zhang et al., 2017).